Spearhead Capital Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Spearhead Capital Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.6M	Sell	202,580 -32,444	-14%	-$370K	2.82%	5
2022 Q2	$2.28M	Hold	235,024	–	–	0.34%	54
2022 Q1	$2.34M	Hold	235,024	–	–	0.29%	56
2021 Q4	$2.77M	Hold	235,024	–	–	0.33%	56
2021 Q3	$2.68M	Hold	235,024	–	–	0.36%	52
2021 Q2	$3.27M	Sell	235,024 -141,821	-38%	-$2.15M	0.45%	56
2021 Q1	$6.97M	Buy	376,845 +106,728	+40%	+$2.18M	1.03%	55
2020 Q4	$4.77M	Hold	270,117	–	–	0.76%	56
2020 Q3	$4.14M	Sell	270,117 -678	-0.3%	-$12.7K	0.79%	56
2020 Q2	$6.9M	Hold	270,795	–	–	1.47%	17
2020 Q1	$4.19M	Buy	+270,795	New	+$4.24M	1.21%	44

Other funds holding KNSA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Spearhead Capital Advisors's KNSA Position: Q3 2022 in Review

Spearhead Capital Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 14% in Q3 2022, selling an estimated $370K and leaving 202,580 shares worth $2.6M. The position accounts for 2.82% of the portfolio, ranked #5.

Spearhead Capital Advisors first reported a position in KNSA in Q1 2020 and has held it in 11 quarters since. The position peaked at $6.97M in Q1 2021. 104 funds tracked by Wall St. Rank hold KNSA as of Q3 2022.

Spearhead Capital Advisors held 202,580 shares of Kiniksa Pharmaceuticals worth $2.6M as of Q3 2022.
Spearhead Capital Advisors sold 32,444 Kiniksa Pharmaceuticals shares in Q3 2022, an estimated $370K.
Kiniksa Pharmaceuticals made up 2.82% of Spearhead Capital Advisors's portfolio in Q3 2022, its #5 holding.
Spearhead Capital Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and has held it in 11 quarters since.
Spearhead Capital Advisors's Kiniksa Pharmaceuticals position peaked at $6.97M in Q1 2021.
104 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.